The trial aims to evaluate the therapy’s tolerability, pharmacokinetics and safety in around 56 healthy volunteers.

Ixinity (trenonacog alfa) can effectively prevent and controlled bleeds in young children with severe or moderately severe ...

Treatment with tuspetinib in combination with Venclexta and Vidaza in newly diagnosed acute myeloid leukemia showed safety ...

Q4 2024 Earnings Call Transcript February 20, 2025 Prothena Corporation plc misses on earnings expectations. Reported EPS is ...

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

Inventiva (IVA) and Hepalys Pharma, a company incorporated in Japan and founded by Catalys Pacific, announced the initiation of the clinical ...

Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN) has ...

Acurx Pharmaceuticals’ DNA Polymerase IIIC Inhibitors receives Japanese patent: Staten Island, New York Thursday, February 20, 2025, 18:00 Hrs [IST] Acurx Pharmaceuticals, Inc., ...

Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN ...

BOSTON, MA, USA I February 19, 2025 I Radiance Biopharma, Inc., ("Radiance" or the "Company"), a biotechnology company, today announced that it has entered ...

Scientific publicationFormycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin 20.02.2025 / 06:30 CET/CESTThe issuer is solely responsible for the content of ...